At 6.7% CAGR, South & Central America Arterial Blood Gas Kits Market is Projected to be worth US$ 51,046.16 thousand by 2031, says Business Market Insights

According to Business Market Insights’ research, the South & Central America arterial blood gas kits market was valued at US$ 30,279.71 thousand in 2023 and is expected to reach US$ 51,046.16 thousand by 2031, recording a CAGR of 6.7% from 2023 to 2031. Development of safe & automated kits and integration of electronic medical records and increasing incidence of respiratory diseases are among the critical factors attributed to drive the South & Central America arterial blood gas kits market growth.

Modern compact arterial blood gas analyzers have the potential to enhance workflow efficiency and improve patient outcomes by facilitating prompt diagnosis and treatment initiation. The kits leverage advanced technologies to provide precise measurements, quality assurance features, and connectivity options for data management and integration with electronic medical records (EMR). Further, arterial blood gas kits can be equipped with wireless connectivity options, due to which they can be seamlessly integrated with the EMR of a hospital information system (HIS). Integration revolutionizes the diagnostic process, empowering healthcare providers with immediate data insights and enabling timely interventions that enhance patient management and clinical decision-making. The burgeoning popularity of telehealth and remote monitoring activities further encourages companies to focus on developing kits that are user-friendly so that they can reduce human errors and improve the overall usability of the product. They are incorporating automated quality control mechanisms and calibration processes in kits to minimize errors and maintain consistent performance of kits. The companies may also integrate kits with safety features such as sample volume monitoring, built-in error detection algorithms, and automatic system checks to ensure the reliability of arterial blood gas kits. In addition, arterial blood gas kits can be introduced with integrated sensors and analyzers that can easily and accurately measure parameters such as partial pressure of oxygen (pO2), electrolytes, partial pressure of carbon dioxide (pCO2), and pH. Thus, the development of user-friendly and automated kits, and the integration of EMR with them are likely to emerge as a notable trend in the arterial blood gas kits market in the future.

On the contrary, the high cost of kits and complications associated with arterial blood sampling aids hamper the growth of South & Central America arterial blood gas kits market.

Based on syringe type, the South & Central America arterial blood gas kits market is bifurcated into luer slip syringe and luer lock syringe. The luer lock syringe segment held 57.6% market share in 2023, amassing US$ 17,434.99 thousand. It is projected to garner US$ 30,222.12 thousand by 2031 to register 7.1% CAGR during 2023–2031.

In terms of type, the South & Central America arterial blood gas kits market is bifurcated into vented and non-vented. The vented segment held 62.9% share of South & Central America arterial blood gas kits market in 2023, amassing US$ 19,036.16 thousand. It is anticipated to garner US$ 32,651.74 thousand by 2031 to expand at 7.0% CAGR during 2023–2031.

By usage, the South & Central America arterial blood gas kits market is bifurcated into pre-set plunger mode and manual aspiration. The pre-set plunger mode segment held 75.7% share of South & Central America arterial blood gas kits market in 2023, amassing US$ 22,914.53 thousand. It is projected to garner US$ 39,667.07 thousand by 2031 to expand at 7.1% CAGR from 2023 to 2031.

Based on application, the South & Central America arterial blood gas kits market is bifurcated into in vitro diagnostics and electrolyte analysis. The in vitro diagnostics segment held 73.4% share of South & Central America arterial blood gas kits market in 2023, amassing US$ 22,224.12 thousand. It is predicted to garner US$ 38,276.64 thousand by 2031 to expand at 7.0% CAGR between 2023 and 2031. The in vitro diagnostics segment held a larger market share in 2023. Furthermore, the in vitro diagnostics segment is sub segmented into pH blood gas, oxygen content, and others.

In terms of needle gauge, the South & Central America arterial blood gas kits market is segmented into less than 23G, 23G to 25G, and greater than 25G. The 23G to 25G segment held 45.6% share of South & Central America arterial blood gas kits market in 2023, amassing US$ 13,813.39 thousand. It is estimated to garner US$ 24,017.20 thousand by 2031 to expand at 7.2% CAGR during 2023–2031.

Based on syringe volume, the South & Central America arterial blood gas kits market is segmented into 1ml, 3ml, and others. The 3ml segment held 46.9% share of South & Central America arterial blood gas kits market in 2023, amassing US$ 14,187.91 thousand. It is projected to garner US$ 25,143.07 thousand by 2031 to expand at 7.4% CAGR from 2023 to 2031.

By end user, the South & Central America arterial blood gas kits market is categorized into hospitals & clinics, diagnostic laboratories, and others. The hospitals & clinics segment held 53.4% share of South & Central America arterial blood gas kits market in 2023, amassing US$ 16,173.93 thousand. It is projected to garner US$ 28,336.66 thousand by 2031 to expand at 7.3% CAGR from 2023 to 2031.

Based on country, the South & Central America arterial blood gas kits market is segmented into Brazil, Argentina, Colombia, and the Rest of South & Central America. Our regional analysis states that Brazil captured 58.8% share of South & Central America arterial blood gas kits market in 2023. It was assessed at US$ 17,816.58 thousand in 2023 and is likely to hit US$ 30,549.90 thousand by 2031, registering a CAGR of 7.0% during 2023 to 2031.

Key players operating in the South & Central America arterial blood gas kits market are Radiometer Medical ApS, Siemens Healthineers AG, AdvaCare Pharma USA LLC, Becton Dickinson and Co, ICU Medical Inc, SunMed Group Holdings LLC (AirLife), SARSTEDT AG & Co KG, and Lepu Medical Technology Beijing Co Ltd., among others.

• In January 2022, ICU Medical acquired Smiths Medical from Smiths Group plc. The Smiths Medical business includes syringe and ambulatory infusion devices, vascular access, and vital care products. Combined with ICU Medical's existing businesses, the two companies create a leading infusion therapy company with estimated pro forma combined revenues of approximately US$ 2.5 billion. The NeoCord ABG kit includes two labels and samplers to accommodate venous and arterial draws.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com